EUCTR2020-005764-62-FR进行中（未招募）1 期
A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1.Written informed consent.
- •2.Male or female between the ages of 18 and 75 years, inclusive, at
- •3.Meets the 2013 American College of Rheumatology/European League
- •Against Rheumatism classificationcriteria for SSc with a total score of =9
- •(Van den Hoogen et al., 2013).
- •4.Classified as having skin involvement proximal to the elbow and knee
- •(diffuse cutaneous SSc subset byLeRoy and Medsger, 2001).
- •5.At the time of enrollment, less than 36 months since the onset of the
- •first SSc manifestation, other thanRaynaud's phenomenon.
- •6.Based on data available through medical history and/or medical
- •records, the subject should have at least 1 ofthe following:
- •a.disease duration =18 months
- •b.increase =3 in mRSS units compared with the last visit within the
- •previous 1 month to 6 months
- •c.involvement of 1 new body area with =2 mRSS units or 2 new body
- •areas with =1 mRSS unit
- •d.documentation of worsening skin thickening for subjects who did not
- •have mRSS performed during theprevious visit
- •e.presence of tendon friction rub at Screening
- •7.Presence of at least 1 of the following features of elevated acute phase
- •reactants at Screening:
- •high-sensitivity C-reactive protein (hsCRP) =0.6 mg/dL (=6 mg/L),
- •erythrocyte sedimentation rate (ESR) =28 mm/hr,
- •platelet count =330 × 109/L (330,000/µL).
- •8.Skin thickening from SSc in the forearm suitable for repeat biopsy.
- •9.mRSS units =15 at Screening.
- •10.FVC =45% predicted at Screening, as determined by spirometry.
- •11.Willing and able to comply with the prescribed treatment protocol
- •and evaluations for the duration of thetrial.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 285
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
排除标准
- •1.Positive for anti-centromere antibodies.
- •2.Diagnosed with sine scleroderma or limited cutaneous SSc.
- •3.Diagnosed with other autoimmune connective tissue diseases, except for fibromyalgia,scleroderma-associated myopathy and secondary Sjogren's syndrome.
- •4.Scleroderma renal crisis diagnosed within 6 months of the Screening Visit.
- •5.Any of the following cardiovascular diseases:
- •a.uncontrolled, severe hypertension (=160/100 mmHg) or persistent
- •low blood pressure (systolic bloodpressure <90 mmHg) within 6 months of Screening,
- •b.myocardial infarction within 6 months of Screening,
- •c.unstable cardiac angina within 6 months of Screening.
- •6.DLCO <40% predicted (corrected for hemoglobin). If severe acute respiratory syndrome coronavirus2 (SARS-CoV-2) exposure is of clinical
- •concern for any subject, consider using a DLCO up to 6 monthsbefore the Screening Visit.
- •7.Pulmonary arterial hypertension (PAH) by right heart catheterization requiring treatment with more than1 oral PAH-approved therapy or any
- •parenteral therapy. Treatment is allowed for erectile dysfunctionand/orRaynaud's phenomenon/digital ulcers.
- •8.Corticosteroid use for conditions other than SSc within 4 weeks prior to Screening (topical steroids fordermatological conditions and
- •inhaled/intranasal/intra-articular steroids are allowed).
- •9.Use of any other non-steroid immunosuppressive agent, small biologic molecule, cytotoxic or anti-fibroticdrug within 4 weeks of Screening,
- •including cyclophosphamide, azathioprine (Imuran®) or otherimmunosuppressive or cytotoxic medication.
- •10.Known active bacterial, viral, fungal, mycobacterial or other infection,
- •including tuberculosis or atypicalmycobacterial disease (fungal infections of nail beds are allowed).
- •11.Use of a United States Food and Drug Administration-approved agent for SSc or an investigational agent forany condition within 90 days or 5
- •half-lives, whichever is longer, prior to Screening or anticipated use during the course of the trial.
- •12.Malignant condition in the past 5 years (except successfully treated basal/squamous cell carcinoma of theskin or cervical cancer in situ).
- •13.Women of childbearing potential or male subjects not agreeing to use highly effective method(s) of birthcontrol throughout the trial and for 1
- •month after last dose of trial drug. Male subjects must refrain fromsperm donation and females from egg/ova donation for this same time period.
- •14.Pregnant or lactating women.
- •15.Current drug or alcohol abuse or history of either within the previous
- •2 years, in the opinion of theInvestigator or as reported by the subject.
- •16.Previous enrollment in this trial or participation in a prior HZN-825 or SAR100842 clinical trial.
- •17.Known history of positive test for human immunodeficiency virus.
- •18.Active hepatitis (hepatitis B: positive hepatitis B surface antigen and
- •positive anti-hepatitis B core antibody[anti-HBcAb] and negative
- •hepatitis B surface antibody [HBsAb] or positive for HBcAb with a
- •positive testfor HBsAb and with presence of hepatitis B virus DNA at
- •Screening; hepatitis C: positive anti-hepatitis Cvirus [anti-HCV] and
- •positive RNA HCV).
- •19.Current alcoholic liver disease, primary biliary cirrhosis or primary
- •sclerosing cholangitis.
- •20.Previous organ transplant (including allogeneic and autologous
- •marrow transplant).
- •21.International normalized ratio >2, prolonged prothrombin time >1.5
- •× the upper limit of normal (ULN) orpartial thromboplastin time >1.5 ×
- •ULN at Screeni
研究者
相似试验
进行中（未招募）
1 期
A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic SclerosisEUCTR2020-005764-62-ESHorizon Therapeutics Ireland DAC300
进行中（未招募）
1 期
A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic SclerosisEUCTR2020-005764-62-NLHorizon Therapeutics Ireland DAC300
进行中（未招募）
1 期
A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic SclerosisDiffuse Cutaneous Systemic SclerosisMedDRA version: 21.0Level: LLTClassification code 10042953Term: Systemic sclerosisSystem Organ Class: 100000004859EUCTR2020-005764-62-GRHorizon Therapeutics Ireland DAC300
进行中（未招募）
1 期
A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic SclerosisDiffuse Cutaneous Systemic SclerosisMedDRA version: 21.0Level: LLTClassification code 10042953Term: Systemic sclerosisSystem Organ Class: 100000004859EUCTR2020-005764-62-PTHorizon Therapeutics Ireland DAC300
进行中（未招募）
1 期
A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic SclerosisDiffuse Cutaneous Systemic SclerosisMedDRA version: 21.0Level: LLTClassification code 10042953Term: Systemic sclerosisSystem Organ Class: 100000004859EUCTR2020-005764-62-DEHorizon Therapeutics Ireland DAC300